TALZENNA Drug Patent Profile
✉ Email this page to a colleague
When do Talzenna patents expire, and when can generic versions of Talzenna launch?
Talzenna is a drug marketed by Pfizer and is included in two NDAs. There are six patents protecting this drug.
This drug has ninety-five patent family members in thirty-one countries.
The generic ingredient in TALZENNA is talazoparib tosylate. Two suppliers are listed for this compound. Additional details are available on the talazoparib tosylate profile page.
DrugPatentWatch® Generic Entry Outlook for Talzenna
Talzenna was eligible for patent challenges on October 16, 2022.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be October 20, 2031. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for TALZENNA?
- What are the global sales for TALZENNA?
- What is Average Wholesale Price for TALZENNA?
Summary for TALZENNA
| International Patents: | 95 |
| US Patents: | 6 |
| Applicants: | 1 |
| NDAs: | 2 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 90 |
| Clinical Trials: | 23 |
| Patent Applications: | 563 |
| Drug Prices: | Drug price information for TALZENNA |
| What excipients (inactive ingredients) are in TALZENNA? | TALZENNA excipients list |
| DailyMed Link: | TALZENNA at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for TALZENNA
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for TALZENNA
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| German Cancer Research Center | Phase 1/Phase 2 |
| Hospital Sultan Ismail | Phase 2 |
| University of Malaya | Phase 2 |
Pharmacology for TALZENNA
| Drug Class | Poly(ADP-Ribose) Polymerase Inhibitor |
| Mechanism of Action | Poly(ADP-Ribose) Polymerase Inhibitors |
US Patents and Regulatory Information for TALZENNA
TALZENNA is protected by six US patents and one FDA Regulatory Exclusivity.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of TALZENNA is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting TALZENNA
Crystalline (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,- 9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ADULT PATIENTS WITH HRR GENE-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) IN COMBINATION WITH ENZALUTAMIDE
Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Crystalline (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,- 9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ADULT PATIENTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BREAST CANCER SUSCEPTIBILITY GENE (BRCA)-MUTATED (GBRCAM) HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER
FDA Regulatory Exclusivity protecting TALZENNA
USE OF TALAZOPARIB IN COMBINATION WITH ENZALUTAMIDE FOR THE TREATMENT OF ADULT PATIENTS WITH HOMOLOGOUS RECOMBINATION REPAIR (HRR) GENE-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC).
Exclusivity Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pfizer | TALZENNA | talazoparib tosylate | CAPSULE;ORAL | 217439-006 | Mar 7, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Pfizer | TALZENNA | talazoparib tosylate | CAPSULE;ORAL | 211651-003 | Sep 20, 2021 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Pfizer | TALZENNA | talazoparib tosylate | CAPSULE;ORAL | 211651-006 | Jun 20, 2023 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Pfizer | TALZENNA | talazoparib tosylate | CAPSULE;ORAL | 217439-004 | Mar 7, 2024 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Pfizer | TALZENNA | talazoparib tosylate | CAPSULE;ORAL | 217439-005 | Mar 7, 2024 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Pfizer | TALZENNA | talazoparib tosylate | CAPSULE;ORAL | 211651-003 | Sep 20, 2021 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for TALZENNA
When does loss-of-exclusivity occur for TALZENNA?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Argentina
Patent: 3502
Patent: SAL TOSILADA DE (8S,9R)-5-FLUORO-8-(4-FLUOROFENIL)-9-(1-METIL-1H-1,2,4-TRIAZOL-5-IL)-8,9-DIHIDRO-2H-PIRIDO[4,3,2-DE]FTALAZIN-3(7H)-ONA CRISTALINA
Estimated Expiration: ⤷ Sign Up
Australia
Patent: 11317040
Patent: Crystalline (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt
Estimated Expiration: ⤷ Sign Up
Patent: 17201564
Patent: CRYSTALLINE (8S,9R)-5-FLUORO-8-(4-FLUOROPHENYL)-9-(1-METHYL-1H-1,2,4-TRIAZOL-5-YL)-8,9-DIHYDRO-2H-PYRIDO[4,3,2-DE]PHTHALAZIN-3(7H)-ONE TOSYLATE SALT
Estimated Expiration: ⤷ Sign Up
Brazil
Patent: 2013009117
Patent: sal tosilato de (8s,9r)-5-fluor-8-(4-fluorefenil)-9-(1-metil-1h-1,2,4-triazol-5-il)-8,9-diidro-2h-pirido[4,3,2-de]ftalazin-3(7h)-ona, método para preparar uma forma cristalina e uso do mesmo,composição farmacêutica e método para tratar um câncer ou um sintoma do mesmo.
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 14581
Patent: SEL TOSYLATE DE LA (8S,9R)-5-FLUORO-8-(4-FLUOROPHENYL)-9-(1-METHYL-1H- 1,2,4-TRIAZOL-5-YL)-8,9-DIHYDRO-2H-PYRIDO[4,3,2-DE]PHTALAZIN-3(7H)-ONE CRISTALLIN (CRYSTALLINE (8S,9R)-5-FLUORO-8-(4-FLUOROPHENYL)-9-(1-METHYL-1H-1,2,4-TRIAZOL-5-YL)-8,9-DIHYDRO-2H-PYRIDO[4,3,2-DE]PHTHALAZIN-3(7H)-ONE TOSYLATE SALT)
Estimated Expiration: ⤷ Sign Up
China
Patent: 3282365
Patent: Crystalline (8S,9R)--fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt
Estimated Expiration: ⤷ Sign Up
Cyprus
Patent: 23356
Estimated Expiration: ⤷ Sign Up
Denmark
Patent: 30146
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 30146
Patent: SEL TOSYLATE DE LA (8S,9R)-5-FLUORO-8-(4-FLUOROPHÉNYL)-9-(1-MÉTHYL-1H- 1,2,4-TRIAZOL-5-YL)-8,9-DIHYDRO-2H-PYRIDO[4,3,2-DE]PHTALAZIN-3(7H)-ONE CRISTALLIN (CRYSTALINE (8S,9R)-5-FLUORO-8-(4-FLUOROPHENYL)-9-(1-METHYL-1H-1,2,4-TRIAZOL-5-YL)-8,9-DIHYDRO-2H-PYRIDO[4,3,2-DE]PHTALAZIN-3(7H)-ONE TOSYLATE SALT)
Estimated Expiration: ⤷ Sign Up
Patent: 57106
Patent: SEL TOSYLATE DE LA (8S,9R)-5-FLUORO-8-(4-FLUOROPHÉNYL)-9-(1-MÉTHYL-1H- 1,2,4-TRIAZOL-5-YL)-8,9-DIHYDRO-2H-PYRIDO[4,3,2-DE]PHTALAZIN-3(7H)-ONE CRISTALLIN (CRYSTALINE (8S,9R)-5-FLUORO-8-(4-FLUOROPHENYL)-9-(1-METHYL-1H-1,2,4-TRIAZOL-5-YL)-8,9-DIHYDRO-2H-PYRIDO[4,3,2-DE]PHTALAZIN-3(7H)-ONE TOSYLATE SALT)
Estimated Expiration: ⤷ Sign Up
Hungary
Patent: 51535
Estimated Expiration: ⤷ Sign Up
Israel
Patent: 5789
Patent: מלח טוזילאט של (5-(9r, 8s-פלואורו-8-(4-פלואורופניל)-9-(1-מתיל-4,2,1-1h- טריאזול-5-יל)- 9,8- דיהידרו-2h-פירידו[2,3,4-דה] פתאלאזינ-3(3h)-און גבישי (Crystalline (8s,9r)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1h-1,2,4-triazol-5-yl)-8,9-dihydro-2h-pyrido[4,3,2-de]phthalazin-3(7h)-one tosylate salt)
Estimated Expiration: ⤷ Sign Up
Patent: 1497
Patent: מלח טוזילאט של (s8, r9)-5-פלואורו-8-(4-פלואורופניל)-9-(1-מתיל-h1- 4,2,1-טריאזול-5-יל)-9,8-דיהידרו-h2-פירידו[2,3,4-דה]פתאלאזינ-3(h3)-און גבישי (Crystalline (8s,9r)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1h-1,2,4-triazol-5-yl)-8,9-dihydro-2h-pyrido [4,3,2-de]phthalazin-3(7h)-one tosylate salt)
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 13540158
Estimated Expiration: ⤷ Sign Up
Patent: 17061526
Patent: 結晶性（８Ｓ，９Ｒ）−５−フルオロ−８−（４−フルオロフェニル）−９−（１−メチル−１Ｈ−１，２，４−トリアゾール−５−イル）−８，９−ジヒドロ−２Ｈ−ピリド［４，３，２−ｄｅ］フタラジン−３（７Ｈ）−オントシレート塩 (CRYSTALINE (8S,9R)-5-FLUORO-8-(4-FLUOROPHENYL)-9-(1-METHYL-1H-1,2,4-TRIAZOL-5-YL)-8,9-DIHYDRO-2H-PYRIDO[4,3,2-de]PHTHALAZIN-3(7H)-ONE TOSYLATE SALT)
Estimated Expiration: ⤷ Sign Up
Patent: 19034951
Patent: 結晶性（８Ｓ，９Ｒ）−５−フルオロ−８−（４−フルオロフェニル）−９−（１−メチル−１Ｈ−１，２，４−トリアゾール−５−イル）−８，９−ジヒドロ−２Ｈ−ピリド［４，３，２−ｄｅ］フタラジン−３（７Ｈ）−オントシレート塩 (CRYSTALLINE (8S,9R)-5-FLUORO-8-(4-FLUOROPHENYL)-9-(1-METHYL-1H-1,2,4-TRIAZOLE-5-YL)-8,9-DIHYDRO-2H-PYRIDO[4,3,2-DE]PHTHALAZINE-3(7H)-ON TOSYLATE)
Estimated Expiration: ⤷ Sign Up
Patent: 20169209
Patent: 結晶性（８Ｓ，９Ｒ）−５−フルオロ−８−（４−フルオロフェニル）−９−（１−メチル−１Ｈ−１，２，４−トリアゾール−５−イル）−８，９−ジヒドロ−２Ｈ−ピリド［４，３，２−ｄｅ］フタラジン−３（７Ｈ）−オントシレート塩 (CRYSTALLINE (8S,9R)-5-FLUORO-8-(4-FLUOROPHENYL)-9-(1-METHYL-1H-1,2,4-TRIAZOL-5-YL)-8,9-DIHYDRO-2H-PYRIDO[4,3,2-de]PHTHALAZIN-3(7H)-ONE TOSYLATE SALT)
Estimated Expiration: ⤷ Sign Up
Patent: 22140637
Patent: 結晶性（８Ｓ，９Ｒ）－５－フルオロ－８－（４－フルオロフェニル）－９－（１－メチル－１Ｈ－１，２，４－トリアゾール－５－イル）－８，９－ジヒドロ－２Ｈ－ピリド［４，３，２－ｄｅ］フタラジン－３（７Ｈ）－オントシレート塩
Estimated Expiration: ⤷ Sign Up
Mexico
Patent: 2563
Patent: SAL TOSILATO DE (8S, 9R) - 5 - FLUORO -8 - (4 - FLUOROFENIL) - 9 - (1 - METIL - 1H - 1, 2, 4 - TRIAZOL - 5 - IL) - 8, 9 - DIHIDRO - 2H - PIRIDO [4, 3, 2 - DE] FTALAZIN - 3 (7H) - ONA. (CRYSTALLINE (8S,9R)-5-FLUORO-8-(4-FLUOROPHENYL)-9-( 1-METHYL-1H-1,2,4-TRIAZOL-5-YL)-8,9-DIHYDRO-2H-PYRIDO[4,3,2-DE]P HTHALAZIN-3(7H)-ONE TOSYLATE SALT.)
Estimated Expiration: ⤷ Sign Up
Patent: 13004195
Patent: SAL TOSILATO DE (8S, 9R) - 5 - FLUORO -8 - (4 - FLUOROFENIL) - 9 - (1 - METIL - 1H - 1, 2, 4 - TRIAZOL - 5 - IL) - 8, 9 - DIHIDRO - 2H - PIRIDO [4, 3, 2 - DE] FTALAZIN - 3 (7H) - ONA. (CRYSTALLINE (8S,9R)-5-FLUORO-8-(4-FLUOROPHENYL)-9-( 1-METHYL-1H-1,2,4-TRIAZOL-5-YL)-8,9-DIHYDRO-2H-PYRIDO[4,3,2-DE]P HTHALAZIN-3(7H)-ONE TOSYLATE SALT.)
Estimated Expiration: ⤷ Sign Up
New Zealand
Patent: 9490
Patent: Crystalline (8s,9r)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1h-1,2,4-triazol-5-yl)-8,9-dihydro-2h-pyrido[4,3,2-de]phthalazin-3(7h)-one tosylate salt
Estimated Expiration: ⤷ Sign Up
Poland
Patent: 30146
Estimated Expiration: ⤷ Sign Up
Portugal
Patent: 30146
Estimated Expiration: ⤷ Sign Up
Russian Federation
Patent: 98606
Patent: КРИСТАЛЛИЧЕСКАЯ ТОЗИЛАТНАЯ СОЛЬ (8S,9R)-5-ФТОР-8-(4-ФТОРФЕНИЛ)-9-(1-МЕТИЛ-1Н-1,2,4-ТРИАЗОЛ-5-ИЛ)-8-9-ДИГИДРО-2Н-ПИРИДО[4,3,2-de]ФТАЛАЗИН-3(7Н)-ОНА (CRYSTALLINE TOSYLATE SALT (8S,9R)-5-FLUORO-8-(4-FLUOROPHENYL)-9-(1-METHYL-1H-1,2,4-TRIAZOL-5-YL)-8-9-DIHYDRO-2H-PYRIDO[4,3,2-de]PHTHALAZIN-3(7H)-ONE)
Estimated Expiration: ⤷ Sign Up
Patent: 13123036
Patent: КРИСТАЛЛИЧЕСКАЯ ТОЗИЛАТНАЯ СОЛЬ (8S,9R)-5-ФТОР-8-(4-ФТОРФЕНИЛ)-9-(1-МЕТИЛ-1Н-1,2,4-ТРИАЗОЛ-5-ИЛ)-8-9-ДИГИДРО-2Н-ПИРИДО[4,3,2-de]ФТАЛАЗИН-3(7Н)-ОНА
Estimated Expiration: ⤷ Sign Up
Singapore
Patent: 9939
Patent: CRYSTALLINE (8S,9R)-5-FLUORO-8-(4-FLUOROPHENYL)-9-(1-METHYL-1H-1,2,4-TRIAZOL-5-YL)-8,9-DIHYDRO-2H-PYRIDO[4,3,2-DE]PHTHALAZIN-3(7H)-ONE TOSYLATE SALT
Estimated Expiration: ⤷ Sign Up
Patent: 201710578T
Patent: CRYSTALLINE (8S,9R)-5-FLUORO-8-(4-FLUOROPHENYL)-9-(1-METHYL-1H-1,2,4-TRIAZOL-5-YL)-8,9-DIHYDRO-2H-PYRIDO[4,3,2-DE]PHTHALAZIN-3(7H)-ONE TOSYLATE SALT
Estimated Expiration: ⤷ Sign Up
Slovenia
Patent: 30146
Estimated Expiration: ⤷ Sign Up
South Africa
Patent: 1302810
Patent: CRYSTALLINE(8S,9R)-5-FLUORO-8-(4-FLUOROPHENYL)-9-(1-METHYL-1H11,2,4-TRIAZOL-5-YL)-8,9-DIHYDRO-2H-PYRIDO[4,3,2-DE]PHTHALAZIN-3(7H)-ONE TOSYLATE SALT
Estimated Expiration: ⤷ Sign Up
South Korea
Patent: 140009181
Patent: CRYSTALLINE (8S,9R)-5-FLUORO-8-(4-FLUOROPHENYL)-9-(1-METHYL-1H-1,2,4-TRIAZOL-5-YL)-8,9-DIHYDRO-2H-PYRIDO[4,3,2-DE]PHTHALAZIN-3(7H)-ONE TOSYLATE SALT
Estimated Expiration: ⤷ Sign Up
Patent: 180069132
Patent: 결정질의 (8S,9R)-5-플루오로-8--9-(1-메틸-1H-1,2,4-트리아졸-5-일)-8,9-디하이드로-2H-피리도[4,3,2-DE]프탈라진-3(7H)-온 토실레이트 염 (8S9R-5--8-4--9-1--1H-124--5--89--2H-[432-DE]-37H- CRYSTALLINE 8S9R-5-FLUORO-8-4-FLUOROPHENYL-9-1-METHYL-1H-124-TRIAZOL-5-YL-89-DIHYDRO-2H-PYRIDO[432-DE]PHTHALAZIN-37H-ONE TOSYLATE SALT)
Estimated Expiration: ⤷ Sign Up
Patent: 190120458
Patent: 결정질의 (8S,9R)-5-플루오로-8--9-(1-메틸-1H-1,2,4-트리아졸-5-일)-8,9-디하이드로-2H-피리도[4,3,2-DE]프탈라진-3(7H)-온 토실레이트 염 (8S9R-5--8-4--9-1--1H-124--5--89--2H-[432-DE]-37H- CRYSTALLINE 8S9R-5-FLUORO-8-4-FLUOROPHENYL-9-1-METHYL-1H-124-TRIAZOL-5-YL-89-DIHYDRO-2H-PYRIDO[432-DE]PHTHALAZIN-37H-ONE TOSYLATE SALT)
Estimated Expiration: ⤷ Sign Up
Patent: 210028747
Patent: 결정질의 (8S,9R)-5-플루오로-8--9-(1-메틸-1H-1,2,4-트리아졸-5-일)-8,9-디하이드로-2H-피리도[4,3,2-DE]프탈라진-3(7H)-온 토실레이트 염 (8S9R-5--8-4--9-1--1H-124--5--89--2H-[432-DE]-37H- CRYSTALLINE 8S9R-5-FLUORO-8-4-FLUOROPHENYL-9-1-METHYL-1H-124-TRIAZOL-5-YL-89-DIHYDRO-2H-PYRIDO[432-DE]PHTHALAZIN-37H-ONE TOSYLATE SALT)
Estimated Expiration: ⤷ Sign Up
Spain
Patent: 16600
Estimated Expiration: ⤷ Sign Up
Taiwan
Patent: 57123
Estimated Expiration: ⤷ Sign Up
Patent: 43858
Estimated Expiration: ⤷ Sign Up
Patent: 1307345
Patent: Crystalline (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt
Estimated Expiration: ⤷ Sign Up
Patent: 1713656
Patent: Crystalline (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering TALZENNA around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Japan | 2022140637 | 結晶性（８Ｓ，９Ｒ）－５－フルオロ－８－（４－フルオロフェニル）－９－（１－メチル－１Ｈ－１，２，４－トリアゾール－５－イル）－８，９－ジヒドロ－２Ｈ－ピリド［４，３，２－ｄｅ］フタラジン－３（７Ｈ）－オントシレート塩 | ⤷ Sign Up |
| Denmark | 2767537 | ⤷ Sign Up | |
| Singapore | 189939 | CRYSTALLINE (8S,9R)-5-FLUORO-8-(4-FLUOROPHENYL)-9-(1-METHYL-1H-1,2,4-TRIAZOL-5-YL)-8,9-DIHYDRO-2H-PYRIDO[4,3,2-DE]PHTHALAZIN-3(7H)-ONE TOSYLATE SALT | ⤷ Sign Up |
| Cyprus | 1123356 | ⤷ Sign Up | |
| Mexico | 2013004195 | SAL TOSILATO DE (8S, 9R) - 5 - FLUORO -8 - (4 - FLUOROFENIL) - 9 - (1 - METIL - 1H - 1, 2, 4 - TRIAZOL - 5 - IL) - 8, 9 - DIHIDRO - 2H - PIRIDO [4, 3, 2 - DE] FTALAZIN - 3 (7H) - ONA. (CRYSTALLINE (8S,9R)-5-FLUORO-8-(4-FLUOROPHENYL)-9-( 1-METHYL-1H-1,2,4-TRIAZOL-5-YL)-8,9-DIHYDRO-2H-PYRIDO[4,3,2-DE]P HTHALAZIN-3(7H)-ONE TOSYLATE SALT.) | ⤷ Sign Up |
| Japan | 2018012698 | ポリ（ＡＤＰ−リボース）ポリメラーゼ（ＰＡＲＰ）のジヒドロピリドフタラジノン阻害剤 (DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP)) | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for TALZENNA
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2767537 | 2019C/551 | Belgium | ⤷ Sign Up | PRODUCT NAME: TALAZOPARIB, OPTIONEEL IN DE VORM VAN EEN FARMACEUTISCH ZOUT; AUTHORISATION NUMBER AND DATE: EU/1/19/1377 20190624 |
| 2767537 | 19C1071 | France | ⤷ Sign Up | PRODUCT NAME: TALAZOPARIB OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/19/1377 20190624 |
| 2767537 | 132019000000153 | Italy | ⤷ Sign Up | PRODUCT NAME: TALAZOPARIB(TALZENNA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/19/1377, 20190624 |
| 2767537 | C201930072 | Spain | ⤷ Sign Up | PRODUCT NAME: TALAZOPARIB, OPCIONALMENTE EN FORMA DE SAL FARMACEUTICAMENTE ACEPTABLE; NATIONAL AUTHORISATION NUMBER: EU/1/19/1377; DATE OF AUTHORISATION: 20190620; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/19/1377; DATE OF FIRST AUTHORISATION IN EEA: 20190620 |
| 2767537 | SPC/GB19/070 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: TALAZOPARIB, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, SUCH AS THE TOSYLATE SALT; REGISTERED: UK EU/1/19/1377 (NI) 20190624; UK PLGB00057-1672 20190624; UK PLGB00057-1673 20190624 |
| 2767537 | 54/2019 | Austria | ⤷ Sign Up | PRODUCT NAME: TALAZOPARIB ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ ODER SOLVAT DAVON; REGISTRATION NO/DATE: EU/1/19/1377 (MITTEILUNG) 20190624 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
